XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.3
Business Segment Information (Notes)
 6 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Business Segment Information
11. Business Segment Information
We operate and report our financial information in three reportable business segments: Healthcare, AST, and Life Sciences. Previously, we had four reportable business segments, however, as a result of the divestiture of our Dental segment, Dental is presented as discontinued operations. Historical information has been retrospectively adjusted to reflect these changes for comparability, as required. For more information, refer to Note 4 titled, "Discontinued Operations." Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income.
Our Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. Our products and services range from infection prevention consumables and capital equipment, as well as services to maintain that equipment; to the repair of re-usable procedural instruments; to outsourced instrument reprocessing services. In addition, our procedural solutions also include endoscopy accessories, instruments, and capital equipment infrastructure used primarily in operating rooms, ambulatory surgery centers, endoscopy suites, and other procedural areas.
Our AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Our technology-neutral offering supports Customers every step of the way, from testing through sterilization.
Our Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device research and manufacturing facilities, in particular those focused on aseptic manufacturing. Our portfolio includes a full suite of capital equipment, consumable products, equipment maintenance and specialty services.
We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company.
For the three and six months ended September 30, 2024 and 2023, revenues from a single Customer did not represent ten percent or more of the Healthcare, AST or Life Sciences segment revenues.
Additional information regarding our segments is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2024, which was filed with the SEC on May 29, 2024.
Financial information for each of our segments is presented in the following table:
 Three Months Ended September 30,Six Months Ended September 30,
 2024202320242023
Revenues:
Healthcare $944,230 $870,056 $1,845,451 $1,688,930 
AST256,737 235,053 506,540 468,152 
Life Sciences127,945 133,095 256,423 264,508 
Total revenues$1,328,912 $1,238,204 $2,608,414 $2,421,590 
Operating income (loss):
Healthcare$228,006 $204,054 $444,893 $402,236 
AST109,902 110,783 227,616 220,373 
Life Sciences53,700 50,284 106,284 100,125 
Corporate(97,129)(87,020)(198,877)(178,893)
Total operating income$294,479 $278,101 $579,916 $543,841 
Less: Adjustments
Amortization of acquired intangible assets (1)
$67,971 $69,846 $135,632 $133,938 
Acquisition and integration related charges (2)
3,205 15,808 5,459 18,045 
Tax restructuring (credits) costs (3)
(561)— (43)9 
Amortization of inventory and property "step up" to fair value (1)
1,402 917 2,793 2,539 
Restructuring charges (credits) (4)
2,796 (23)30,878 (4)
Income from operations$219,666 $191,553 $405,197 $389,314 
(1) For more information regarding our recent acquisitions and divestitures, refer to Note 3 titled, "Business Acquisitions and Divestitures."
(2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.
(3) Costs incurred in tax restructuring.
(4) For more information regarding our restructuring efforts, refer to Note 2 titled, "Restructuring."
Additional information regarding our fiscal 2025 and fiscal 2024 revenue is disclosed in the following tables:
 Three Months Ended September 30,Six Months Ended September 30,
 2024202320242023
Healthcare:
Capital equipment$249,732 $254,905 $464,371 $493,004 
Consumables341,707 306,025 685,061 586,306
Service352,791 309,126 696,019 609,620 
Total Healthcare Revenues $944,230 $870,056 $1,845,451 $1,688,930 
AST:
Capital equipment$8,805 $1,754 $9,893 $2,628 
Service247,932 233,299 496,647 465,524 
Total AST Revenues$256,737 $235,053 $506,540 $468,152 
Life Sciences:
Capital equipment$23,012 $35,438 $49,488 $66,429 
Consumables72,125 59,409 141,943 121,107 
Service32,808 38,248 64,992 76,972 
Total Life Sciences Revenues$127,945 $133,095 $256,423 $264,508 
Total Revenues$1,328,912 $1,238,204 $2,608,414 $2,421,590 
Three Months Ended September 30,Six Months Ended September 30,
2024202320242023
Revenues:
Ireland$22,802 $20,399 $44,996 $40,435 
United States979,528 909,651 1,926,418 1,765,439 
Other locations326,582 308,154 637,000 615,716 
Total Revenues
$1,328,912 $1,238,204 $2,608,414 $2,421,590